期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

TWEAK在动脉粥样硬化中的研究进展 被引量：1

Progression of TWEAK in Atherosclerosis
下载PDF
导出
摘要 动脉粥样硬化被描述为一种慢性炎症性疾病,在这一过程中包括细胞聚集、增殖、新生血管形成和管壁硬化。TWEAK是肿瘤坏死因子超家族的新成员之一,有许多生物学功能,能诱导炎症反应、激活细胞生长、刺激黏附分子及金属蛋白酶表达、诱导细胞凋亡等。在体外培养的细胞中有潜在的致动脉粥样硬化效应,是参与动脉粥样硬化的重要因素之一。 Atherosclerosis is described as an inflammatory disease given that the main components of chronic inflammation are present in this process ： cell recruitment, proliferation, neovascularization, and sclerosis. TNF-like weak inducer of apoptosis （TWEAK） is a member of the TNF superfamiliy, which is involved in induction of inflammation, activation of cell growth, expression of adhesion molecules and matrix metalloproteinases and stimulation of apoptosis. The interaction of TWEAK with its receptor Fn14 has potential proatherogenic effects in cultured cells which may be important in the pathogenesis of atherosclerosis.
作者 吴勇波 曾和松
机构地区 华中科技大学同济医学院附属同济医院心内科
出处 《心血管病学进展》 CAS 2008年第6期917-919,共3页 Advances in Cardiovascular Diseases
关键词 TWEAK Fn14 动脉粥样硬化 TNF-like weak inducer of apoptosis Fn14 atherosclerosis
分类号 R543.5 [医药卫生—心血管疾病]
  • 相关文献

参考文献1

二级参考文献22

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献344

同被引文献25

  • 1CHICHEPORTICHE Y, BOURDON P R, XU H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis[J]. J Biol Chem, 1997, 272(51 ) : 32401 - 32410.
  • 2HAN E S, MEKASHA S, INGALLS R R. Fibroblast growth factor- inducible 14 (Fnl4) is expressed in the lower genital tract and may play a role in amplifying inflammation during infection[J]. J Reprod Immunol, 2010, 84( 1 ) : 16 -23.
  • 3BURKLY L C, MICHAELSON J S, ZHENG T S. TWEAK/Fnl4 pathway: an immunological switch for shaping tissue responses [ J ]. Immunol Rev, 2011,244 ( 1 ) : 99 - 114.
  • 4BURKLY L C, MICHAELSON J S, HAHM K, et al. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/ Fni4 pathway in health and disease [ J ]. Cytokine, 2007, 40 (1) : 1 -16.
  • 5MUNOZ GARCIA B, MARTIN VENTURA J L, MARTINEZ E, et al. Fnl4 is upregulated in cytokine - stimulated vascular smooth muscle cells and is expressed in human carotid athemsclerotic plaques : modulation by atorvastatin [ J ]. Stroke, 2006, 37 ( 8 ) : 2044 - 2053.
  • 6PESIC S, RADENKOVIC M, GRBOVIC L. Endothelial dysfunc- tion: mechanisms of development and therapeutic options [ J ]. Med Pregl, 2006, 59(7/8) : 335 -341.
  • 7HARADA N, NAKAYAMA M, NAKANO H, et al. Pro - inflam- matory effect of TWEAK./Fnl4 interaction on human umbilical vein endothelial cells [ J]. Biochem Biophys Res Commun, 2002, 299 (3) : 488 - 493.
  • 8MARTIN VENTURA J L, BLANCO COLIO L M, MUNOZ GAR- CIA B, et al. NF - kappaB activation and Fas ligand overexpres- sion in blood and plaques of patients with carotid atheroselerosis: potential implication in plaque instability [ J ]. Stroke, 2004, 35 (2) : 458 -463.
  • 9MORENO J A, SASTRE C, MADRIGAL MATUTE J, et al. HMGB1 expression and secretion are increased via TWEAK - Fnl4 interaction in atherosclerotic plaques and cultured monocytes [J]. Arterioscler Thromb Vasc Biol, 2013, 33 (3) : 612 - 620.
  • 10CHORIANOPOULOS E, JARR K, STEEN H, et al. Soluble TWEAK is markedly upregnlated in patients with ST - elevation myocardial infarction and related to an adverse short - term out- come [ J ]. Atherosclerosis, 2010, 211 ( 1 ) : 322 - 326.

引证文献1

心血管病学进展
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部